18 September 2026 | Friday | News
EB Development, a company owned directly or indirectly by funds managed by IK Partners and former reference shareholders of Eurobio Scientific (FR0013240934, ALERS), including NextStage and managers and directors of the Company, including CEO Denis Fortier, announces its intention to file a public withdrawal offer (the "Offer"), followed by a mandatory withdrawal (the "Mandatory Withdrawal") in conjunction with the publication of Eurobio Scientific's half-year results scheduled for September 24, 2026.
To date, EB Development directly owns 90.14% of the shares and voting rights of Eurobio Scientific1. The Offer would be denominated at the price of the voluntary public purchase offer made in 2024, i.e. 25.30 euros per share representing premiums of +26.39%, +22.71% and +16.05% respectively compared to the average 20-day, 60-day and 120-day-day volume-weighted prices at the closing stock exchange rate as of September 16, 2026.
On the proposal of an ad hoc committee constituted by the Board of Directors of the Company and composed of a majority of independent directors in accordance with the provisions of Article 261-1 of the General Regulations of the Autorité des marchés financiers (the "AMF"), the Board of Directors of Eurobio Scientific has appointed the firm Ledouble, represented by Mr. Olivier Cretté and Mr. Jonathan Nilly (64, rue de la Boétie, 75008 Paris), as an independent expert responsible for writing a report
including a certificate of fairness on the financial terms of the Offer and the absence of related agreements likely to affect equal treatment between shareholders.
The completion of this offer remains subject to its filing with the Autorité des marchés financiers as well as to a decision of conformity that the latter would issue at the end of its examination.
After the closing of the Offer, EB Development will implement a mandatory withdrawal procedure to the extent that minority shareholders hold less than 10% of Eurobio Scientific's capital and voting rights. Minority shareholders will receive compensation equal to the price of the Offer under the Mandatory Withdrawal.
© 2026 Biopharma Boardroom. All Rights Reserved.